According to one study, in pembrolizumab monotherapy in patients with advanced NSCLC with high PD-L1 expression, the pre-treatment TCR diversity obtained from peripheral blood may be used as a good non-invasive biomarker of ORR, PFS, and toxicity, but it cannot be used as an biomarker of OS [54]. Here, CD274 is linked to non-small cell lung carcinoma.